US President Donald Trump has imposed 100% tariff on branded and patented drugs. These new charges will be implemented from 1 October 2025. These rules will apply to drugs that are not producing in the US or whose plant is not under construction. This decision of America is going to have a major impact on India’s pharmaceutical exports.
India’s dependence on the US market
According to the US Census Bureau, in 2024, the US imported about 233 billion dollars and medicinal products. India is called the ‘Pharmacy of the World’, as it offers about 20% of the supply of global generic drugs and 60% of the vaccine. Apart from this, India is the home of US FDA-recognized production plants outside the US.
In 2024-25, India exported medicines worth more than $ 30 billion worldwide.
During the same period, America was India’s largest export destination, where India sent about 31% (about 3.6 billion dollars in 2024 and $ 3.7 billion in the first half of 2025).
Tariff will increase pressure on India
The tariff will currently be applied only to patented drugs, but experts believe that complex generic and specialty drugs can also be included in the future. Indian companies such as Dr. Reddy, Sun Pharma, Lupine and Orobindo are leading in the US market through low -priced generic drugs. These medicines meet ten out of nine prescriptions in the US, but take only 1.2% of the country’s health budget.
potential impact
Prices will increase: Cost cost burden may increase on American patients and government health programs like Medicare/Medicade.
Supply disrupted: Indian companies had already warned that high tariffs could cause drug supply blockage and lack of drugs in the US.
Dependence on China: Industry representatives say that the US may have to depend more on China for life saving drugs when the tariff is implemented, which may threaten its national security.
Possible opportunities for India
Some industry leaders consider it an opportunity for self -sufficiency. Dadachanji Group Rishad Dadchanji said that this crisis would inspire Indian companies to find new markets, increase investment in R&D and develop partnerships.
conclusion
If the US persists on its tariff decision, the Indian pharma industry may suffer a short -term shock, but in a long time this step may force India to move faster in the direction of market diversification and innovation.
